Tyler Martin, MD is the Chairman and CEO of Adjuvance Technologies, a vaccine and adjuvant development company, working on an improved shingles vaccine and next-generation saponin adjuvants. He previously played instrumental roles in the development and regulatory approval of the adjuvanted vaccines Fluad and Heplisav-B. Dr. Martin has held senior leadership positions in biotech companies including Chiron, Sangamo, and Dynavax. He has led teams that filed more than 100 Investigational New Drug (IND) Applications. 

© 2024 BioFutureTM. All Rights Reserved

Produced by